Netherton Investments led a $25m Series A extension round in Engitix.

Netherton Investments, a fund investing on behalf of Mike Platt, the co-founder and Managing Director of BlueCrest Capital Management, led a $25m Series A extension round in Engitix, a biotech company developing therapies that target the extracellular matrix to treat cancer and fibrosis. “Closing this financing strengthens our ability to translate Engitix’s unique ECM understanding into a growing pipeline of targeted therapeutics. Our platform and dataset position us to accelerate preclinical development across oncology and fibrosis programs and build differentiated, ECM-targeted therapeutics with the potential to meaningfully improve patient outcomes,” Giuseppe Mazza, Engitix CEO and Co-Founder.